iMDx reports Q3 2025 net loss of $10.9M, advances toward FDA submission for GraftAssureDx by year-end

Insight Molecular Diagnostics Inc.

2025-Q3 EPS reported -$0.91 vs consensus -$0.21 ▼ miss (-325.4%)

Revenue $260k from lab services; gross margin 53.5%; net loss $10.9M ($0.34/sh); cash $20.2M.
On track to submit GraftAssureDx for FDA review by year-end; expect mid-2026 commercial launch.
19 transplant centers engaged with GraftAssure technology; goal of 20 by year-end; 11 clinical trial sites.
Operating expenses $11.2M include $3.4M non-cash contingent consideration change; R&D up 18% QoQ to $3.9M.
New VP Marketing Steven Tahmooressi hired; registry study of 5,000 patients planned; expanding into heart transplant testing.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.